Using two structurally-distinct small-molecule pan-PIM inhibitors, we show that blocking PIM activity concurrent with MET inhibition resensitizes savolitinib-resistant cells in vitro. Interestingly, when we assessed the in vivo efficacy of combining the PIM inhibitor with savolitinib, in savolitinib resistant H1993 clone 11 tumors we observed similar anti-tumor activity as seen with savolitinib alone in H1993 parental tumors. Here, PIM1 is linked to neoplasm.